ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Are Drugs Becoming More Lipophilic Over Time?

  Get a deeper look into how drug lipophilicity has evolved over time, its impact on drug development, and the need for new technology to enable new more complex drugs.

• Prefillable Syringe Plungers: A Solution For Low Temperature Storage

  Review a study with 1 mL long glass and polymer-based syringes and with 2.25 mL glass syringes. Explore the impacts on plunger movement, container closure integrity, and break loose and extrusion force.

• Solubility With Lipid-Based Technologies For Oral & Injectable Formulations

  Innovative approaches in developing formulations can help to improve a drug's safety and efficacy. Explore the decision for selecting the best-suited technology for formulating a complex molecule.

• The Dynamic Regulatory Environment Of Drug-Device Combination Products

  Examine the dynamic regulatory environment of drug-device combination products as well as concrete steps to take to navigate regulatory complexities and decrease time to market.

• Crystallization Process Development: Peptide Crystallization

  Whether performed during formation of an API or as a means to purify intermediates, achieving control of nucleation and crystal growth is critical to designing a successful peptide crystallization process.

• From Regulators To PUPSIT: Notes On Annex 1 Revision Implementation

  Kevin Smyth, a biochemical engineer with 30 years of experience in the pharmaceutical industry, offers insights and expertise in working with firms to understand what regulators seek to meet new standards.

• Amorphous Formulations For Insoluble Drugs: Rational Design & Practical Approaches On Formulation Screening & Development

  The issues associated with amorphous formulations include solid state stability, chemical stability, reproducibility of API manufacturing, impurity of API, in vitro in vivo performance, process and scale-up.

• Streamline Microbial Process Development To Reach Toxicology Trials Faster

  For biopharmas looking to outsource their early phase development, consider working with a CDMO partner that has the knowledge and experience to navigate microbial fermentation and complex process development.

• Solving For The Future Of Drug Delivery

  Next-gen therapeutics require equally advanced delivery systems—localized, personalized, and precise—to ensure efficacy, safety, and scalability. Delivery is now a central driver of innovation.

• Unlocking New Possibilities For Treating Rare Genetic Diseases

  With over 7,000 rare diseases, the potential for nanomedicine to revolutionize treatment is immense. While polymer nanoparticles hold great promise, several challenges remain.